Evidence map›Paper›PMID 37322036›Full record

ArticleNature communications2023

SEC-seq: association of molecular signatures with antibody secretion in thousands of single human plasma cells.

Rene Yu-Hong Cheng, Joseph de Rutte, Cade Ellis K Ito, Andee R Ott, Lucie Bosler, Wei-Ying Kuo, Jesse Liang, Brian E Hall, David J Rawlings, Dino Di Carlo and 1 more

Abstract read
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Humanized mice enableMolecular therapy. Advances · 2026
    Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Targeting human plasma cells using regulated BCMA CAR T cells eliminates circulating antibodies in humanized mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rene Yu-Hong Cheng *Center of Immunotherapy and Immunity, Seattle Children Research Institute, Seattle, WA, 98101, USA.
Joseph de Rutte *Partillion Bioscience, Los Angeles, CA, 90095, USA.
Cade Ellis K ItoCenter of Immunotherapy and Immunity, Seattle Children Research Institute, Seattle, WA, 98101, USA.
Andee R OttCenter of Immunotherapy and Immunity, Seattle Children Research Institute, Seattle, WA, 98101, USA.
Lucie BoslerPartillion Bioscience, Los Angeles, CA, 90095, USA.
Wei-Ying KuoPartillion Bioscience, Los Angeles, CA, 90095, USA.
Jesse LiangPartillion Bioscience, Los Angeles, CA, 90095, USA.
Brian E HallLuminex corporation, Seattle, WA, 98119, USA.
David J RawlingsCenter of Immunotherapy and Immunity, Seattle Children Research Institute, Seattle, WA, 98101, USA.ORCID http://orcid.org/0000-0002-0810-1776
Dino Di CarloPartillion Bioscience, Los Angeles, CA, 90095, USA. dicarlo@ucla.edu.
Richard G JamesCenter of Immunotherapy and Immunity, Seattle Children Research Institute, Seattle, WA, 98101, USA. rickerj@u.washington.edu.ORCID http://orcid.org/0000-0002-2302-7367

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Mechanisms mediating resistance to ibrutinib in Non-Hodgkin's lymphomaR01CA201135 · NCI · SEATTLE CHILDREN'S HOSPITAL · PI JAMES, RICHARD GOFF · 2017 to 2021
$2.1M
Role of Dock8 in Mucosal ImmunityR01AI140626 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI JAMES, RICHARD GOFF, PILIPONSKY, ADRIAN M · 2018 to 2022
$1.7M
High-throughput antibody discovery directly from B cells using nanovial technologyR43GM144000 · NIGMS · PARTILLION BIOSCIENCE CORPORATION · PI DE RUTTE, JOSEPH · 2021 to 2021
$355k
NCI NIH HHS P30 CA016042NCI NIH HHS R01 CA201135NIAID NIH HHS R01 AI140626NIGMS NIH HHS R43 GM144000
6 · The paper itself

Abstract

The secreted products of cells drive many functions in vivo; however, methods to link this functional information to surface markers and transcriptomes have been lacking. By accumulating secretions close to secreting cells held within cavity-containing hydrogel nanovials, we demonstrate workflows to analyze the amount of IgG secreted from single human B cells and link this information to surface markers and transcriptomes from the same cells. Measurements using flow cytometry and imaging flow cytometry corroborate the association between IgG secretion and CD38/CD138. By using oligonucleotide-labeled antibodies we find that upregulation of pathways for protein localization to the endoplasmic reticulum and mitochondrial oxidative phosphorylation are most associated with high IgG secretion, and uncover surrogate plasma cell surface markers (e.g., CD59) defined by the ability to secrete IgG. Altogether, this method links quantity of secretion with single-cell sequencing (SEC-seq) and enables researchers to fully explore the links between genome and function, laying the foundation for discoveries in immunology, stem cell biology, and beyond.

Indexed as

B-LymphocytesPlasma CellsBiomarkersCell MembraneHumansImmunoglobulin GBiomarkersImmunoglobulin G

Identifiers

PMID37322036
PMCPMC10272111

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.